Roger Farris
Family · Highland, INNPI 1902491558
Payments from drug & device makers
Across 133 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$333
- AstraZeneca$290
- AbbVie$284
- Novo Nordisk$231
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$194
- Exact Sciences$136
- plus $959 from 20 others
What the payments were for
- Food & beverage$2,41299%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $333 |
| AstraZeneca(2 entities) | 13 | $290 |
| AbbVie | 14 | $284 |
| Novo Nordisk | 16 | $231 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $194 |
| Exact Sciences | 8 | $136 |
| Bayer | 5 | $109 |
| Mylan Specialty L.p. | 5 | $99 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Vanda Pharmaceuticals Inc. | 2 | $72 |
| Almatica Pharma LLC | 4 | $72 |
| Lilly USA, LLC | 4 | $72 |
| Verona Pharma, Inc. | 3 | $59 |
| GSK | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Dexcom, Inc. | 3 | $44 |
| Electromed, Inc. | 4 | $43 |
| Pfizer | 3 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Vertex | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Cequr Corporation | 1 | $11 |
How this compares
$2,427 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $67,296 |
| FarxigaDapagliflozin Propanediol | 26 | $43,555 |
| JardianceEmpagliflozin | 20 | $35,768 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $25,147 |
| EliquisApixaban | 28 | $20,846 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,603 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $19,649 |
| CaplytaLumateperone Tosylate | 12 | $19,620 |
| LinzessLinaclotide | 13 | $19,139 |
| XareltoRivaroxaban | 18 | $18,973 |
| JanuviaSitagliptin Phosphate | 13 | $17,151 |
| MounjaroTirzepatide | 14 | $15,135 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 371 | $12,832 |
| UbrelvyUbrogepant | 12 | $10,565 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $10,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $290 | $79,10992 claims |
| Novo NordiskOzempic | $231 | $67,29661 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $45,02938 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $56 | $38,03462 claims |
| AbbVieLinzess, Ubrelvy | $284 | $29,70425 claims |
| PfizerEliquis | $42 | $20,84628 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $194 | $19,62012 claims |
| Lilly USA, LLCMounjaro | $72 | $15,13514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Highland
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.